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a  b  s  t  r  a  c  t
In the  UK,  a national  HPV  immunisation  programme  was  implemented  in  2008  for  girls  aged  12–13  years.
In  addition  a catch-up  programme  was  implemented  for older  girls  up to  18 years  of  age  from  2009  to
2011,  with  an  uptake  rate  of  49.4%.  Information  about  future  uptake  of  cervical  screening  according  to
vaccination  statistics  is important  in  order  to understand  the  impact  of  the  vaccination  programme  and
implications  for  a national  cervical  screening  programme.  We  analysed  data  on a cohort  of women  who
had  been  offered  the HPV  vaccine  in the  catch-up  programme  and  were  invited  for  cervical  screening
between  2010  and  2012  in  Wales  (n = 30,882),  in  a record-linked  database  study,  to  describe  the  cervical
screening  uptake  and  clinical  outcome  according  to HPV  vaccination  status.
In  our  cohort,  48.5%  (n = 14,966)  women  had  had  HPV  vaccination  and  45.9%  (n  = 14,164)  women
attended for  cervical  screening.  Women  who  were  unvaccinated  were  less  likely  to attend  cervical  screen-
ing  (adjusted  OR 0.58;  95%  CI  (0.55, 0.61)).  Of those  who  attended  for screening,  13.9%  of  vaccinated
women  had abnormal  cytology  reported  compared  to  16.7%  of  women  who  were  unvaccinated.  Women
who  lived  in  areas with  high  levels  of social  deprivation  were  less  likely  to be vaccinated  (Quintile  5  OR
0.48  95%  CI (0.45, 0.52))  or  attend  cervical  screening  (Quintile  5  OR  0.70;  95%  CI (0.65, 0.75))  compared
to  those  who  lived  in the  least  deprived  areas.
These  data  highlight  the  need  for  new  strategies  to  address  inequalities  in  cervical  screening  uptake  and
can  inform  further  mathematical  modelling  work  to clarify  the impact  of the  HPV  vaccination  programme
 incidon  future  cervical  cancer
. Introduction
There are two commercially available Human Papillomavirus
HPV) vaccines licensed by the FDA for prevention of cervical can-
er: Cervarix® (GlaxoSmithKline) and Gardasil® (Sanoﬁ Pasteur
SD). Both vaccines prevent acquisition of HPV16 and 18 infections
1–5] responsible for approximately 70% of cervical cancers and
hey offer some cross protection against other oncogenic strains
f HPV [6–10]. Clinical trial data has indicated that the vaccines
re highly effective in preventing new cases of HPV16 and 18
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eproduction in any medium, provided the original author and source are credited.
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associated diseases, with signiﬁcantly lower rates of high grade
Cervical Intraepithelial Neoplasia (CIN) and Adenocarcinoma in-
situ diagnosed [11–15]. Prevention of cancer is more likely in
women who receive the HPV vaccination prior to exposure to the
virus [6,16].
In the UK, a national HPV vaccination programme using the
bivalent vaccine, Cervarix® was  introduced in September 2008 in
schools, with a recommended 3 doses administered to girls aged
12–13 years. A two-year catch-up vaccine arm was  added for older
girls who potentially would still beneﬁt from the immune response
induced by the HPV vaccine. Such a comprehensive national vac-
cination programme is expected to change the epidemiology of
cervical cancer in the UK population. However, the impact of such
a programme will depend on vaccine uptake, cervical screening
uptake and the risk of exposure in women  who  are not vaccinated
and not screened. If women  who are unvaccinated choose not to
attend for cervical screening, and have high risk of exposure to
HPV, then the impact of the vaccination programme will be less
reserved.
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han predicted, with potential to increase inequalities in cervical
ancer incidence in the population.
In order to understand the likely impact of the HPV vaccination
rogramme for cervical cancer incidence it is important to under-
tand the screening behaviour of women according to whether or
ot they have been vaccinated. In this study we report the factors
ssociated with HPV vaccination uptake, cervical screening uptake
nd clinical outcome according to HPV vaccination status for the
rst cohort of women who had been offered the HPV vaccine and
ere invited for cervical screening within a national population-
ased cervical screening programme in Wales.
. Materials and methods
.1. Study population
The study population comprised women who  were born
etween 1 st September 1990 and 29th February 1992 who were
esident in Wales on 1 st April 2012. These women  would have
een offered HPV vaccination as part of the catch-up campaign,
nd invited for routine cervical screening between 1st September
010 and 29th February 2012 as they turned 20 years of age, or
fter moving into Wales.
.2. Data sources
.2.1. Secure Anonymised Information Linkage databank
The Centre for Improvements in Population Health through
-Records (CIPHeR) has established the Secure Anonymised Infor-
ation Linkage (SAIL) databank, which brings together and
nonymously links a wide range of person-based data [17]. This
atabank includes existing routinely collected datasets such as the
elsh Demographic Service (all people registered with a Welsh
r English General Practitioner), Cervical Screening Wales (CSW)
data from a population based national screening programme [18])
nd the National Community Child Health Database (NCCHD) (child
ealth records of children who since 1987 have been born, treated
including vaccination status) or resident in Wales [19]). Using
hese linked datasets we identiﬁed all women resident in Wales on
st April 2012 within the cohort birth range, 1st September 1990
o 29th February 1992.
HPV vaccination data (number of doses and dates administered)
ere extracted from both the CSW and NCCHD databases and tri-
ngulated to give a complete vaccination history for the cohort of
omen. Data on cervical screening uptake and clinical outcome
ere obtained from the CSW databases. Data on birth character-
stics of the women such as maternal age at birth, gestational age
t birth and childhood vaccination status (for any childhood vac-
inations as per the recommended schedule for immunisations in
he UK) were extracted from the NCCHD. Data on quintile of social
eprivation was based on Townsend score calculated using data
rom the 2001 Census, based on the woman’s area of residence on
pril 1st 2012.
.3. Statistical analyses
All analyses were carried out using SPSS v19. Univariate binary
ogistic regression was used to describe the association between
ach variable (quintile of social deprivation, maternal age at birth,
estational age at birth, childhood vaccination) and (i) HPV vac-
ination uptake, (ii) cervical screening uptake and (iii) cervical
creening abnormality. Multivariate binary logistic regression was
sed to obtain odds ratios for the association between HPV vaccina-
ion uptake and cervical screening uptake, adjusted for the variables
isted above.(2014) 1828–1833 1829
Women  were categorised as having been partially HPV vacci-
nated if only 1 or 2 of the recommended 3 doses were recorded,
and fully HPV vaccinated if 3 or more doses were recorded.
Childhood vaccination was deﬁned as any childhood vaccination
recorded on the NCCHD database (excluding HPV vaccination). A
cervical screening cytological abnormality was deﬁned as a result
of borderline changes, mild/moderate/severe dyskaryosis or worse.
Results reported as inadequate or negative were considered not
abnormal for this analysis.
Data were missing for some variables in the cohort: maternal
age (29.7%); gestational age (33.9%); and childhood vaccinations
(21.1%). We  carried out a complete case analysis and analysis that
included the missing data as a separate category. The results were
similar in both models so we have presented the results with miss-
ing data as a separate category.
The analyses were restricted to cases with available social depri-
vation data based on the Townsend score for deprivation quintile
[20], therefore excluded 12 women resident in Wales on 1st April
2012 for whom data on area of residence was missing.
3. Results
There were 33,601 women on the NHS AR for the study
cohort and time period. Data were available for 30,882 women
from the CSW and 24,351 women from the NCCHD (Fig. 1).
14,966/30,882 (48.5%) women  had HPV partial or full vaccina-
tion and 14,164/30,882 (45.9%) women had attended for cervical
screening. 2427/30,882 (7.9%) women  had HPV partial vaccina-
tion and attended for cervical screening and 5579/30,882 (18.1%)
women had HPV full vaccination and attended for cervical screen-
ing.
Table 1 describes the characteristics of women according
to HPV vaccine uptake. HPV vaccination status was deﬁned
as (i) full HPV vaccination with 3 or more recorded doses
(n = 10,109/30,882; 32.7%); (ii) partial HPV vaccination with
1–2 doses (n = 4857/30,882; 15.7%); (iii) not HPV vaccinated
(n = 15,916/30,882; 51.5%).
There was a statistically signiﬁcant relationship between uptake
of the HPV vaccine and social deprivation quintile (Table 1). Women
from the most afﬂuent quintile (Quintile 1) were more likely to
have had partial (19.2%) or full (39.5%) HPV vaccination. Conversely
women from the most deprived quintile (Quintile 5) had the highest
number of women  that had not been HPV vaccinated and the lowest
number of women with reported partial and full HPV vaccination
(59.2%, 14.4% and 26.3%, respectively).
The highest proportion of women not vaccinated was  observed
for the groups with maternal age under 20 years and 20–24 years
(55.4% and 48.7%, respectively) compared to groups whose moth-
ers were older and this was  statistically signiﬁcant (OR 0.62; 95%
CI (0.56, 0.68) and OR 0.80; 95% CI (0.75, 0.86), respectively).
There was  no clear relationship between gestational age and HPV
vaccination.
Table 2 describes the uptake of cervical screening according
to characteristics of women. There was  a signiﬁcant relationship
between uptake of cervical screening and social deprivation score.
Women  from the most deprived areas (Quintile 5) were less likely
to have attended for cervical screening than women from the least
deprived areas (Quintile 1) (41.3% compared to 50.1%, respectively;
univariate OR 0.69; 95% CI (0.65, 0.75)).
Women  who were fully vaccinated were more likely to have
attended for cervical screening than women who had not been
vaccinated and this was statistically signiﬁcant (55.2% compared to
38.7%, respectively, OR 0.51 95% CI (0.49, 0.54)). In women who  had
attended cervical screening, 8006/14,164 (56.5%) had received at
least one dose of the HPV vaccine. In women who had not attended
1830 H. Beer et al. / Vaccine 32 (2014) 1828–1833
udy ﬂo
f
o
s
T
HFig. 1. Stor cervical screening, 6960/16,718 (41.6%) had received at least
ne dose of the HPV vaccine.
Reported cervical screening cytological abnormalities in the
tudy population are shown in Table 3. There was a clear
able 1
PV vaccination uptake according to characteristics of women  in the cohort.
Variable Number (% for
each variable)
Fully HPV
vaccinated (%)
Par
vac
Quintile 1 (least deprived) 4093 (13.3) 1616 (39.5) 787
Quintile 2 4323 (14.0) 1680 (38.9) 708
Quintile  3 5737 (18.6) 1993 (34.7) 901
Quintile  4 6940 (22.5) 2241 (32.3) 104
Quintile  5 (most deprived) 9789 (31.7) 2579 (26.3) 141
Maternal age group 1 (25–29 years) 7576 (24.5) 2917 (38.5) 137
Maternal age group 2 (under 20 years) 2163 (7.0) 572 (26.4) 393
Maternal age group 3 (20–24 years) 6313 (20.4) 2089 (33.1) 114
Maternal age group 4 (30–34 years) 4093 (13.3) 1723 (42.1) 698
Maternal age group 5 (35+ years) 1578 (5.1) 605 (38.3) 282
Maternal age group 6 (missing data) 9159 (29.7) 2203 (24.1) 957
Gestational age group 1 (37+ weeks) 19,187 (62.1) 7115 (37.1) 341
Gestational age group 2 (under 36 weeks) 1218 (3.9) 435 (35.7) 210
Gestational age group 3 (missing data) 10,477 (33.9) 2559 (24.4) 123
No  childhood vaccination 278 (0.9) 134 (48.2) 69 
Childhood vaccination 24,073 (78.0) 8726 (36.2) 433
Missing  childhood vaccination 6531 (21.1) 1249 (19.1) 450w chart.relationship between HPV vaccination and cytological results with
women attending cervical screening who had full HPV vaccina-
tion having the lowest proportion of abnormal cytology reported
compared to those not vaccinated (OR 1.24; 95% CI (1.12, 1.37)).
tially HPV
cinated (%)
Not HPV
vaccinated (%)
Univariate odds
ratio (95% CI)
Adjusted odds
ratio (95% CI)
 (19.2) 1690 (41.3)
 (16.4) 1935 (44.8) 0.87 (0.80, 0.95) 0.90 (0.82, 0.98)
 (15.7) 2843 (49.6) 0.72 (0.66, 0.78) 0.83 (0.76, 0.90)
8 (15.1) 3651 (52.6) 0.63 (0.60, 0.69) 0.79 (0.73, 0.85)
3 (14.4) 5797 (59.2) 0.48 (0.45, 0.52) 0.7 (0.62, 0.72)
8 (18.2) 3281 (43.3)
 (18.2) 1198 (55.4) 0.62 (0.56, 0.68) 0.65 (0.59, 0.71)
9 (18.2) 3075 (48.7) 0.80 (0.75, 0.86) 0.83 (0.78, 0.89)
 (17.1) 1672 (40.9) 1.11 (1.02, 1.20) 1.09 (1.01, 1.18)
 (17.9) 691 (43.8) 0.98 (0.88, 1.09) 0.97 (0.87, 1.09)
 (10.4) 5999 (65.5) 0.40 (0.38, 0.43) 1.09 (0.96, 1.24)
4 (17.8) 8658 (45.1)
 (17.2) 573 (47.0) 0.93 (0.82, 1.04) 0.95 (0.84, 1.07)
3 (11.8) 6685 (63.8) 0.47 (0.44, 0.49) 0.81 (0.73, 0.90)
(24.8) 75 (27.0)
8 (18.0) 11,009 (45.7) 0.44 (0.34, 0.57) 0.42 (0.32, 0.55)
 (6.9) 4832 (74.0) 0.13 (0.10, 0.17) 0.14 (0.11, 0.18)
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Table  2
Cervical Screening uptake according to characteristics of women  in the cohort.
Variable Number (% for
each variable)
Screened (%) Not screened (%) Univariate odds
ratio (95% CI)
Adjusted odds
ratio (95% CI)
Quintile 1 (least deprived) 4093 (13.3) 2052 (50.1) 2041 (49.9)
Quintile 2 4323 (14.0) 2188 (50.6) 2135 (49.4) 1.019 (0.936, 1.110) 1.038 (0.952, 1.132)
Quintile 3 5737 (18.6) 2645 (46.1) 3092 (53.9) 0.851 (0.785, 0.922) 0.942 (0.868, 1.023)
Quintile 4 6940 (22.5) 3239 (46.7) 3701 (53.3) 0.870 (0.806, 0.940) 1.026 (0.947, 1.111)
Quintile 5 (most deprived) 9789 (31.7) 4040 (41.3) 5749 (58.7) 0.699 (0.650, 0.752) 0.911 (0.844, 0.984)
Maternal age group 1 (25–29 years) 7576 (24.5) 3982 (52.6) 3594 (47.4)
Maternal age group 2 (under 20 years) 2163 (7.0) 1075 (49.7) 1088 (50.3) 0.892 (0.810, 0.981) 0.964 (0.875, 1.062)
Maternal age group 3 (20–24 years) 6313 (20.4) 3284 (52.0) 3029 (48.0) 0.979 (0.915, 1.046) 1.015 (0.949, 1.086)
Maternal age group 4 (30–34 years) 4093 (13.3) 2050 (50.1) 2043 (49.9) 0.906 (0.839, 0.977) 0.887 (0.821, 0.958)
Maternal age group 5 (35+ years) 1578 (5.1) 755 (47.8) 823 (52.2) 0.828 (0.743, 0.923) 0.831 (0.745, 0.928)
Maternal age group 6 (missing data) 9159 (29.7) 3018 (33.0) 6141 (67.0) 0.444 (0.417, 0.472) 0.702 (0.617, 0.799)
Gestational age group 1 (37+ weeks) 19,187 (62.1) 9910 (51.6) 9277 (48.4)
Gestational age group 2 (under 36 weeks) 1218 (3.9) 557 (45.7) 661 (54.3) 0.789 (0.702, 0.886) 0.799 (0.710, 0.898)
Gestational age group 3 (missing data) 10,477 (33.9) 3697 (35.3) 6780 (64.7) 0.510 (0.486, 0.536) 1.005 (0.906, 1.114)
No  childhood vaccination 278 (0.9) 110 (39.6) 168 (60.4)
Childhood vaccination 24,073 (78.0) 12,178 (50.6) 11,895 (49.4) 1.564 (1.228, 1.991) 1.415 (1.105, 1.813)
Missing childhood vaccination 6531 (21.1) 1876 (28.7) 4655 (71.3) 0.616 (0.481, 0.787) 0.840 (0.654, 1.078)
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Partial HPV vaccinated 4857 (15.7) 2427 (
Full  HPV vaccinated 10,109 (32.7) 5579 (
here was no relationship between reported cytological abnormal-
ty and social deprivation quintile, maternal age, gestational age or
revious childhood vaccination.
Table 4 presents attendance for cervical screening and detection
f abnormalities for women  in each vaccination group, stratiﬁed
y quintile of deprivation. Results indicate that HPV vaccination
nd social deprivation quintile are predictors of uptake of cervical
creening but do not predict detection of abnormalities.
. Discussion
This is the ﬁrst UK study to investigate uptake of cervical screen-
ng following implementation of the HPV vaccination programme
n the catch-up group. In contrast to concerns that vaccination
ould have a negative impact on a woman’s decision to attend
or cervical screening, uptake of the HPV vaccine was  positively
orrelated to uptake of cervical screening. Social deprivation was
he main factor affecting uptake of both the HPV vaccine and
ervical screening, with the highest levels of non-participation
bserved in the most deprived quintile (59.2% unvaccinated and
8.7% unscreened compared with 41.3% and 49.9% in the least
eprived quintile).
able 3
ervical Screening results according to characteristics of women in the cohort.
Variable Number (% for
each variable)
Abnormal (%) 
Quintile 1 (least deprived) 2052 (14.5) 318 (15.5) 
Quintile 2 2188 (15.4) 344 (15.7) 
Quintile  3 2645 (18.7) 378 (14.3) 
Quintile  4 3239 (22.9) 507 (15.7) 
Quintile 5 (most deprived) 4040 (28.5) 633 (15.7) 
Maternal age group 1 (25–29 years) 3982 (28.1) 634 (15.9) 
Maternal age group 2 (under 20 years) 1075 (7.6) 184 (17.1) 
Maternal age group 3 (20–24 years) 3284 (23.2) 500 (15.2) 
Maternal age group 4 (30–34 years) 2050 (14.5) 312 (15.2) 
Maternal age group 5 (35+ years) 755 (5.3) 105 (13.9) 
Maternal age group 6 (missing data) 3018 (21.3) 445 (14.7) 
Gestational age group 1 (37+ weeks) 9910 (70.0) 1560 (15.7) 
Gestational age group 2 (under 36 weeks) 557 (3.9) 72 (12.9) 
Gestational age group 3 (missing data) 3697 (26.1) 548 (14.8) 
No  childhood vaccination 110 (0.8) 19 (17.3) 
Childhood vaccination 12,178 (86.0) 1901 (15.6) 
Missing  childhood vaccination 1876 (13.2) 260 (13.9) 
Not  HPV vaccinated 6158 (43.5) 1031 (16.7) 
Partial  HPV vaccinated 2427 (17.1) 371 (15.3) 
Full  HPV vaccinated 5579 (39.4) 778 (13.9) 9758 (61.3) 0.512 (0.487, 0.539) 0.580 (0.551, 0.611)
2430 (50.0) 0.811 (0.757, 0.869) 0.789 (0.737, 0.846)
4530 (44.8)
In women  who  attended for cervical screening, HPV vacci-
nation had a protective effect with the lowest proportion of
cytological abnormalities detected (86.1% normal cytology in fully
vaccinated compared with 83.3% in the unvaccinated women;
see Table 3). Although social deprivation affected uptake of
both health services investigated, in this study population, social
deprivation score was  not associated with cytological result.
The implementation of the HPV vaccination programme within
schools has helped to reduce the impact of social deprivation
on uptake of this health service with more than 80% uptake of
all three doses of the HPV vaccine in girls aged 12–13 years
[21].
The main strength of this study was the large sample size from
an unselected population-based cohort utilizing record linkage of
routinely collected data on HPV vaccinations and cervical screen-
ing. Quality of data, particularly the HPV vaccination history, was
strengthened by the use of combined data from both the CSW and
NCCHD datasets.We are conﬁdent of the quality of the data used in this analysis as
the HPV vaccination rates for this cohort are identical to published
rates. The national statistics reported 32.8% of women had received
all 3 doses of the vaccine in the birth cohorts 1st September 1990
Not abnormal (%) Univariate odds
ratio (95% CI)
Adjusted odds
ratio (95% CI)
1734 (84.5)
1844 (84.3) 1.02 (0.86, 1.20) 1.01 (0.86, 1.20)
2267 (85.7) 0.91 (0.773, 1.07) 0.91 (0.77, 1.07)
2732 (84.3) 1.01 (0.87, 1.18) 1.01 (0.87, 1.18)
3407 (84.3) 1.01 (0.88, 1.17) 1.02 (0.87, 1.18)
3348 (84.1)
891 (82.9) 1.09 (0.91, 1.31) 1.06 (0.88, 1.27)
2784 (84.8) 0.95 (0.84, 1.08) 0.94 (0.83, 1.07)
1738 (84.8) 0.95 (0.82, 1.110) 0.96 (0.82, 1.11)
650 (86.1) 0.85 (0.68, 1.07) 0.86 (0.69, 1.07)
2573 (85.3) 0.91 (0.80, 1.04) 1.05 (0.81, 1.36)
8350 (84.3)
485 (87.1) 0.80 (0.617, 1.02) 0.79 (0.62, 1.02)
3149 (85.2) 0.93 (0.838, 1.04) 0.95 (0.77, 1.16)
91 (82.7)
10,277 (84.4) 0.89 (0.54, 1.46) 0.86 (0.51, 1.43)
1616 (86.1) 0.77 (0.46, 1.29) 0.67 (0.40, 1.12)
5127 (83.3) 1.24 (1.12, 1.37) 1.27 (1.15, 1.41)
2056 (84.7) 1.11 (0.97, 1.27) 1.10 (0.97, 1.26)
4801 (86.1)
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Table 4
Cervical screening participation and detection of abnormalities in each vaccination group, stratiﬁed by deprivation quintile.
HPV Vaccinated QUINTILE Screened (%) Abnormal (%)
Not HPV vaccinated Quintile 1 (least deprived) 712 (42.1) 119 (16.7)
Quintile 2 806 (41.7) 130 (16.1)
Quintile 3 1107 (38.9) 167 (15.1)
Quintile 4 1474 (40.4) 266 (18.0)
Quintile 5 (most deprived) 2059 (35.5) 349 (16.9)
Partially HPV vaccinated Quintile 1 (least deprived) 408 (51.8) 61 (15.0)
Quintile 2 382 (54.0) 61 (16.0)
Quintile 3 427 (47.4) 64 (15.0)
Quintile 4 539 (51.4) 82 (15.2)
Quintile 5 (most deprived) 671 (47.5) 103 (15.4)
Fully  HPV vaccinated Quintile 1 (least deprived) 932 (57.7) 138 (14.8)
Quintile 2 1000 (59.5) 153 (15.3)
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[1] La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W.  HPV vaccineQuintile 3 
Quintile 4
Quintile 5 (most dep
o 21st August 1991 and 1st September 1992 to 31st August 1992
PHW COVER Report 96 [22])
It is important to note that our results are based on analysis of
omen from the catch-up arm of the HPV vaccination programme.
hese women were older, and were not all in school and inequal-
ties in coverage have been observed and reported [21]. Bowyer
t al. quantitatively assessed the knowledge and awareness of HPV
nd the vaccine, amongst schoolgirls who had already been offered
he HPV vaccine in the targeted UK vaccination programme [23].
n this cohort, knowledge about HPV infection was  relatively low,
nd only 53.1% participants were aware that HPV could cause cervi-
al cancer. Approximately half of the participants were aware that
ervical screening was still required after HPV vaccination. In our
ata analyses, although the women studied were from the catch-
p arm of the programme, we observed approximately half of the
accinated cohort attending cervical screening (55.2%).
Analysis of factors potentially affecting uptake of health services
vailable for primary cervical cancer prevention in the UK, high-
ighted that women who originate from more socially deprived
reas are less likely to engage with the services available. More-
ver, 9758/30,882 (31.6%) had neither attended for screening nor
eceived the HPV vaccine. However, although social deprivation
ffected the initial engagement, once women engaged, at least in
his age group, there was no signiﬁcant difference in clinical out-
ome. Cervical cancer rates are higher in women from more socially
eprived backgrounds [24]. However, data from our study suggests
hat this is a consequence of women from more socially deprived
reas not engaging with the current primary cervical cancer pre-
ention strategies in the UK.
In women offered HPV vaccination through the catch-up arm
f the programme, this study shows a protective effect with a
eduction in cytological abnormalities from 16.7% in unvaccinated
omen to 13.9% in vaccinated women. However, the level of abnor-
alities detected in the vaccinated women is still relatively high,
otentially reﬂecting acquisition of the virus prior to vaccination.
his data suggests that the catch-up arm of the vaccination pro-
ramme  has not had a substantial protective effect and a higher
mpact on cytological abnormalities is anticipated in the target
roup, who may  not have been exposed to the virus prior to vac-
ination. Women  who have chosen to receive the HPV vaccination
nd attend for cervical screening may  be more health conscious,
nd this may  be reﬂected in their sexual behaviours. It is therefore
ossible that they may  be less likely to become infected with HPV,
ccounting for the reduction seen in the proportion of cytological
bnormalities.The ﬁndings reported here emphasise the need to promote fur-
her engagement with health services in more socially deprived
reas with a focus on younger age groups to enhance the potential1111 (55.7) 147 (13.2)
1226 (54.7) 159 (13.0)
 1310 (50.8) 181 (13.8)
beneﬁt of prevention programmes in early diagnosis and treatment
long term. The HPV vaccination programme represents an ideal
opportunity to convey the beneﬁt of prevention programmes and
reinforcement of this message is needed.
5. Conclusions
Uptake of HPV vaccination was  positively correlated with
uptake of cervical screening, and cytology results indicate that vac-
cination has a protective effect against an abnormal result. Women
from more socially deprived areas engage less with cervical cancer
prevention healthcare services. New strategies to enhance uptake
of screening services need to be directed at young women with a
focus on areas classiﬁed as socially deprived.
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